English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Haemostatic parameters were measured serially for 3 days in 58 infants, within 2 hours of birth. Twelve (21%) maintained normal coagulation profiles, whereas 46 (79%) had abnormal profiles. The abnormal group were randomly allocated to a control (23) and treatment subgroup (23).Treatment consisted of infusions of platelets, fibrinogen (cryoprecipitate) and/or factor II, VII, IX &amp; X concentrate – whichever was appropriate, and repeated when necessary. Detailed post-mortem studies were performed on all infants who died.  The results revealed a lower incidence of intraventricular haemorrhage in the treated subgroup, but this was not statistically significant. There was no difference in mortality between the two subgroups. No deleterious effects due to the administration of blood products;in particular, DIC or local thrombosis was not observed.  It is concluded that although efforts to maintain normal haemostasis in these high risk neonates are possible and may be safe, they are without demonstrable benefit.

Blood Product Infusions to Maintain Normal Haemostasis Parameters in Low Birth Weight Neonates